Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC

Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC

Les analyses moléculaires et la classification des adénocarcinomes bronchiques ont conduit au développement de thérapies ciblées sélectives visant à améliorer le contrôle de la maladie et la survie des patients. ALK (anaplastic lymphoma kinase) est un récepteur tyrosine kinase de la famille des réce...

Full description

Bibliographic Details
Main Author:	Recondo, Gonzalo
Other Authors:	Université Paris-Saclay (ComUE)
Language:	en
Published:	2019
Subjects:	Résistance aux thérapies ciblées Alk Cancer du poumon Resistance to targeted therapies Lung cancer
Online Access:	http://www.theses.fr/2019SACLS248/document

Similar Items

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
by: Hao Huang
Published: (2018-11-01)

Epissage Alternatif d'ATG16L1b : un rôle dans l'échappement des tumeurs pulmonaires aux thérapies anti-EGFR
by: Hatat, Anne-Sophie
Published: (2018)

Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras
by: Xiaoling Song, et al.
Published: (2021-09-01)

Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
by: Paul Hofman
Published: (2021-01-01)

The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
by: Brandon Golding, et al.
Published: (2018-02-01)

KRAS mutation as a mechanism of resistance to Alectinib in ALK rearranged NSCLC
by: Ullas Batra, et al.
Published: (2021-03-01)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
by: Naoki Haratake, et al.
Published: (2019-09-01)

Coexisting of COX7A2L–ALK, LINC01210–ALK, ATP13A4–ALK and Acquired SLCO2A1–ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report
by: Cai C, et al.
Published: (2020-08-01)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01)

Therapeutic Sequencing in ALK<sup>+</sup> NSCLC
by: Mei Elsayed, et al.
Published: (2021-01-01)

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
by: Geeta Geeta Sharma, et al.
Published: (2018-02-01)

Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
by: Amanda J.W. Gibson, BSc (Hons), et al.
Published: (2021-04-01)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-12-01)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
by: Liu D, et al.
Published: (2018-07-01)

Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement
by: Camila B. Xavier, et al.
Published: (2021-12-01)

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
by: David König, et al.
Published: (2020-06-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
by: Zilan Song, et al.
Published: (2015-01-01)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
by: Deng L, et al.
Published: (2018-09-01)

Recent Advances and Prospect of Advanced Non-small Cell Lung Cancer Targeted  Therapy: Focus on Small Molecular Tyrosine Kinase Inhibitors
by: Guowei ZHANG, et al.
Published: (2017-04-01)

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
by: Schrock AB, et al.
Published: (2020-04-01)

Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review
by: Zhichao Liu, et al.
Published: (2018-01-01)

Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
by: Rui Kitadai, et al.
Published: (2019-02-01)

Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer
by: Quan ZHANG, et al.
Published: (2017-01-01)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
by: Xing Huang
Published: (2018-02-01)

Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction
by: Shimada M, et al.
Published: (2017-06-01)

Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
by: Paola Ulivi
Published: (2016-07-01)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-07-01)

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
by: Fan JS, et al.
Published: (2018-03-01)

Clinical Meaning of EML4-ALK Fusion Gene in Non-small Cell Lung Cancer
by: Wei HAN, et al.
Published: (2013-02-01)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01)

Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
by: Ling Zhang, et al.
Published: (2018-06-01)

Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC
by: Ying Dai, et al.
Published: (2018-01-01)

Current approaches to therapy of ALK-positive non-small cell lung cancer
by: К. К. Laktionov, et al.
Published: (2021-06-01)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
by: Muhammad Khan, et al.
Published: (2019-01-01)

Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
by: S. G. Bagrova, et al.
Published: (2019-12-01)

Caractérisation des réseaux d’interactions protéiques associés aux mutations oncogéniques principales retrouvées dans le cancer du poumon non à petites cellules
by: Beganton, Benoît
Published: (2017)

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
by: Aguado C, et al.
Published: (2018-03-01)

Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview
by: Delphine Antoni, et al.
Published: (2021-05-01)

ALK inhibitors, a pharmaceutical perspective
by: Arturo eGalvani, et al.
Published: (2012-02-01)